Utilizing Recently Approved Biosimilars in Clinical Practice

This is a video synopsis/summary of a panel discussion involving Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services at Emory Healthcare and the Winship Cancer Institute; Alice B. Gottlieb, MD, PhD, clinical professor and medical director in the Department of Dermatology at the Icahn School of Medicine at Mount Sinai; Bincy Abraham, MD, MS, professor of clinical medicine in the Academic Division of Gastroenterology and Hepatology at Houston Methodist Hospital; Jamie T. Brogan, APRN, nurse practitioner at Northwestern Medicine; and Vibeke Strand, MD, biopharmaceutical consultant and adjunct clinical professor in the Division of Immunology and Rheumatology at Stanford University School of Medicine.

The discussion focuses on the evolving landscape of biosimilars, specifically the role of adalimumab biosimilars, in dermatology, gastroenterology, and rheumatology. Gottlieb highlights the exclusive use of infliximab and rituximab biosimilars in her dermatology practice, expressing interest in upcoming adalimumab biosimilars and emphasizing the importance of interchangeability. Abraham, in gastroenterology, stresses the significance of maintaining stability for patients on adalimumab due to the potential consequences of disease flares. Strand, in rheumatology, anticipates the use of adalimumab biosimilars, emphasizing the preference for those with interchangeable designations and citing reassuring data on immunogenicity.

The panel discusses the impact of biosimilars on patient stability, with Haumschild underscoring the importance of avoiding complications or disease progression. The conversation covers the challenges of payer coverage decisions and potential switches to biosimilars. Brogan contributes insights into the auto substitution process, highlighting the need for shared decision-making and patient education.

Video synopsis is AI-generated and reviewed by editorial staff.